2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 252-254
Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

962 US trends in prophylaxis treatment, intracranial hemorrhage, and central venous access device complications during the emicizumab era

Robert F Sidonio, Robert Schuldt2, Lucy Lee, PharmD3, Janet S Lee, PhD, PharmD4
1 Aflac Cancer & Blood Disorders Center, Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Atlanta, Georgia, United States, Emory University School of Medicine, Atlanta, Georgia, United States
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States

Background: Emicizumab is a subcutaneously injected, bispecific antibody directed against factor (F)IXa- and FX that is indicated for routine prophylaxis treatment for people with hemophilia A (PwHA). Emicizumab received US Food and Drug Administration (FDA) approval in 2017 for PwHA with FVIII inhibitors (expanded in 2018 to also include those without FVIII inhibitors). Prior to the implementation of emicizumab prophylaxis, prophylactic FVIII clotting factor concentrates were administered intravenously (IV), but IV access is challenging in infants, who have a higher risk of intracranial hemorrhage (ICH) than the general population, and can particularly benefit from a subcutaneous option allowing early prophylaxis initiation. Subcutaneous emicizumab also reduces the need for central venous access devices (CVADs) that can have related complications and infections; these risks are also elevated in the pediatric population. The approval of emicizumab in the US may be associated with decreased incidence of CVAD-related complications and ICH over time among PwHA in the US.

Aims: To describe US trends over time in incidence of CVAD-related complications and ICH, and the proportion of PwHA on prophylaxis since the FDA approved emicizumab.

Methods: This retrospective observational cohort study used national adjudicated medical and pharmacy claims data from IQVIA PharMetrics® Plus. Individuals were required to have at least two outpatient or one inpatient claim for hemophilia A (International Classification of Diseases, Tenth Revision diagnosis code D66) any time during the study period (1/1/2016 to 12/31/2024) and continuous medical and pharmacy benefits for at least 12 months before and after the first observed claim with a hemophilia A diagnosis (index date). Patients were excluded if they had diagnosis codes for other rare bleeding disorders (eg, hemophilia B, acquired hemophilia A and von Willebrand disease). Study outcomes included the proportion of PwHA on any prophylaxis including emicizumab, incidence rates of CVAD-related complications (including infection, thrombosis, and mechanical complications) and incidence rates of ICH (including intraventricular, intraparenchymal, subarachnoid, subdural and epidural bleeds) in the US. Rates are reported per 1000 person-years. Prophylaxis use, CVAD-related events and ICH were identified based on previously published claims-based algorithms. Descriptive statistics were used to summarize baseline patient characteristics. Sensitivity analyses were performed to test the robustness of the CVAD-related and ICH event definitions. Exact Poisson confidence intervals were used to calculate CVAD and ICH event rates. Wilson score confidence intervals were calculated for proportion-based outcomes. Select outcomes were stratified by age and sex.

Results: A total of 3497 PwHA were included in the study (median age, 34.0 years; 66% male; 74% with commercial and 17% with Medicaid insurance types). Approximately 10%-29% of PwHA were on any prophylaxis depending on the calendar year. Among PwHA identified as being on prophylaxis, the proportion of PwHA receiving emicizumab increased from 0% in 2016 to 81% in 2024, largely driven by males and the 2- to 12-year-old age group. Over this 9-year study period, a total of 161 CVAD-related complications were identified. The annual incidence rates of CVAD-related complications decreased from 49.3 (95% CI, 35.3-66.6) in 2016 to 14.1 (7.1-25.3) in 2024. The downward trend in CVAD-related complications was driven by the 2- to 12-year-old age group. The annual incidence rates of ICH (n=10 events) varied from 0 (95% CI, 0-4.7) to 3.1 (0.6-9.0) per 1000 person-years. A clear trend was not observed due to the small number of ICH events, which all occurred among male PwHA. 

Conclusions: Since its FDA approval, emicizumab use has increased among PwHA in the US and has shifted standard of care away from FVIII or bypassing agent prophylaxis. The incidence of CVAD-related complications decreased over time among PwHA in the US, corresponding with the trend in emicizumab uptake. A clear trend in ICH was not observed due to the small number of events, and future research should include the development of updated and validated claims-based algorithms to identify and better capture ICH events.

Robert F Sidonio: Genentech, Inc./F. Hoffmann-La Roche Ltd - Honoraria; Hema Biologics - Honoraria; LFB - Honoraria; Vega - Honoraria; Pfizer - Honoraria; Octapharma - Honoraria; BioMarin - Honoraria; Guardian Therapeutics - Honoraria; Takeda - Honoraria; Novo Nordisk - Honoraria; Hemab - Honoraria; Sanofi - Honoraria; Takeda - Research Funding; Octapharma - Research Funding; LFB - Research Funding; Hema Biologics - Research Funding; Sanofi - Consultancy (Includes expert testimony); uniQure - Consultancy (Includes expert testimony)